Three trends in the antibody-drug conjugate (ADC) market
Drug Discovery World
JUNE 1, 2023
According to NCBI, most of the ADCs developed so far are for use in the treatment of cancer, but there is plenty of potential for using ADCs to treat other diseases 1. To overcome this challenge, Synaffix has developed an innovative technology platform that can rapidly and efficiently convert any antibody into an ADC.
Let's personalize your content